Department of Obstetrics and Gynecology, Ankara University Faculty of Medicine, Ankara, Turkey.
J Gynecol Oncol. 2011 Mar 31;22(1):57-60. doi: 10.3802/jgo.2011.22.1.57.
Port-site metastases in gynecological malignancies subsequent to laparoscopy have been reported with an incidence of 1.1-16%. These metastases tend to be disappearing after primary debulking surgery and subsequent primary chemotherapy. Local resection, chemotherapy and/or radiotherapy have been defined in the management of these metastases with enhanced clinical success. However, in extremely rare cases these metastases were also defined very early during neoadjuvant chemotherapy. Herein, we present two ovarian cancer cases which are clinically diagnosed with port site metastasis during neoadjuvant chemotherapy following diagnostic laparoscopy. Although neoadjuvant chemotherapy is sometimes needed in cases of fully advanced ovarian cancers, port-site metastasis may be encountered during neoadjuvant chemotherapy. The possible poor prognosis of these patients, especially those who have ascites, should make us careful in performing diagnostic laparoscopy with preventive measures for port-site metastasis and to start the chemotherapy immediately.
腹腔镜术后妇科恶性肿瘤的切口部位转移已有报道,其发病率为 1.1%-16%。这些转移灶在初次肿瘤细胞减灭术和随后的初次化疗后往往会消失。对于这些转移灶,局部切除术、化疗和/或放疗已被定义为治疗方法,其临床效果有所增强。然而,在极少数情况下,这些转移灶在新辅助化疗的早期也有明确诊断。在此,我们介绍了两例卵巢癌病例,这些病例在诊断性腹腔镜检查后新辅助化疗期间被临床诊断为切口部位转移。虽然在完全晚期的卵巢癌病例中有时需要新辅助化疗,但在新辅助化疗期间可能会发生切口部位转移。这些患者的预后可能较差,尤其是那些有腹水的患者,这应使我们在进行诊断性腹腔镜检查时小心谨慎,采取预防切口部位转移的措施,并立即开始化疗。